betaFeedback

WorksComputer Science

Doubly Robust Learning of Heterogeneous Survival Treatment Effects under Time-Varying Treatments

Abstract

Estimating heterogeneous survival treatment effects (HSTEs) from time-to-event data under time-varying treatments is important in fields such as medicine (e.g., to decide which sequence of treatments is better in terms of survival probability). However, this task is challenging because treatment decisions, patient characteristics, and censoring probability often evolve together, requiring sequential adjustment for both treatments and censoring. Existing survival learners mostly consider a single baseline treatment assignment, while longitudinal treatment-effect learners typically assume uncensored outcomes. In this paper, we introduce a novel doubly robust learner for heterogeneous survival treatment effects under time-varying treatments and history-dependent censoring. Our framework separates the intervention window from the survival horizon, with treatment prescribed for a finite period, after which care follows its natural course. We further establish the favorable theoretical properties of Neyman-orthogonality, rate double robustness and quasi-oracle efficiency. The framework accommodates flexible machine learning models for nuisance estimation and treatment-effect regression. We evaluate our learners through several numerical experiments, demonstrating their effectiveness.

Introduction

In medicine, personalized treatment decisions rarely occur only once in time. In many clinical settings (e.g., [30, 37]), treatments are administered repeatedly over time, while the outcome of interest is a time-to-event endpoint such as death [16], relapse [38], or disease progression [44]. Estimating how alternative treatment sequences affect survival for a patient with a particular observed history is therefore central to individualized decision-making. In this paper, we aim to estimate heterogeneous survival treatment effects (HSTEs) under time-varying treatments and history-dependent censoring.

This task poses several fundamental challenges. First, treatment decisions may depend on time-varying patient characteristics that are themselves affected by previous treatments. This produces time-varying confounding and invalidates standard adjustment strategies that condition only on baseline information [39, 40, 13], requiring sequential adjustment strategies instead. Second, survival outcomes are subject to right-censoring. In a time-varying setting, the probability of remaining under observation may depend on the evolving patient history, including treatment-affected prognostic variables. Consequently, censoring may be informative given the history available at the initial treatment decision, even when it is conditionally independent of the potential event time given the evolving history. This makes it necessary to adjust for censoring sequentially as well, making the problem more challenging than standard causal survival settings with a single baseline treatment [e.g. 24, 9]. Finally, the clinically relevant intervention and outcome windows need not coincide: a protocol may prescribe treatment for a finite period, while its effect on survival is evaluated at a later evaluation time after subsequent care has returned to its natural course.

Most existing methods for heterogeneous treatment effects estimation capture only parts of these challenges. Causal survival learners typically handle a single baseline treatment (e.g., Curth et al., [6]; Cui et al., [5]; Frauen et al., [9]), where censoring is assumed conditionally independent of the event time given a fixed baseline information set and can therefore be handled without sequential censoring adjustment. In our time-varying setting, in contrast, censoring may depend on evolving, treatment-affected histories, requiring adjustment throughout follow-up. On the other hand, longitudinal causal learners handle time-varying treatments but generally assume fully observed outcomes (Lim et al., [27]; Li et al., 2021; Melnychuk et al., [29]; Frauen et al., [8]), so they do not handle censoring. A small literature comes closer to HSTE estimation under time-varying treatments, with Abraich [1] being our closest work. However, this work remains tied to a particular model architecture, relies on a single nuisance component and does not provide favorable learning guarantees such as double robustness.

In this paper, we develop a model-agnostic framework for learning HSTEs under time-varying treatments and history-dependent censoring. At a landmark time tt, we compare survival under alternative treatment sequences imposed for LL decision times, followed by natural-course treatment, with the evaluation time t+τt+\tau potentially later (see Figure 1). This separation allows us to study finite, clinically actionable interventions. We derive complementary identification strategies based on gg-computation and inverse-probability weighting.

Figure 1. Longitudinal intervention and survival estimand. At landmark tt, treatment is prescribed according to aˉt:t+L−1\bar{a}_{t:t+L-1} for LL decision times. Treatment subsequently follows its natural assignment mechanism, while survival is evaluated at t+τt+\tau, where τ≥L\tau\ge L.

Building on these representations, we introduce a novel

learner that has several favorable learning properties: double robustness (Kang and Schafer, [20]), which allows consistency under misspecification of one of two complementary nuisance components; Neyman-orthogonality (Foster and Syrgkanis, [7]), which removes first-order sensitivity to nuisance-estimation error; and quasi-oracle efficiency (Nie and Wager, [33]), whereby under suitable nuisance-rate conditions the learner matches the convergence rate of its oracle counterpart. Thus, the learner combines longitudinal continuation regressions with treatment and censoring mechanisms in an orthogonal pseudo-outcome, and remains consistent if either the continuation regressions are correctly specified or both probability mechanisms are correctly specified. Its construction permits flexible machine-learning models for nuisance estimation and the final effect regression.

Our contributions are threefold:1 (1) we formulate and identify heterogeneous survival treatment effects for finite-duration longitudinal interventions followed by natural-course treatment under history-dependent censoring, and derive several baseline learners based on complementary adjustment strategies. (2) we introduce a novel doubly robust and Neyman-orthogonal learner for HSTE estimation under time-varying treatments and censoring. (3) we establish its theoretical properties, including (rate) double robustness, Neyman-orthogonality and quasi-oracle efficiency, and validate the proposed learner through synthetic, semi-synthetic, and real-world experiments.

Related Work

HSTE estimation with static treatments. Several approaches have been proposed to estimate HSTEs under a single treatment assignment using baseline covariates. For example, Curth et al. [6] learn treatment-specific hazard functions through representation balancing, while Cui et al. [5] use adaptive forest neighborhoods. More recently, Frauen et al. [9], Xu et al. (2024), and Morzywolek et al. [32] develop model-agnostic, doubly robust and Neyman-orthogonal survival learners. However, the previous causal methods are limited to a single treatment assignment and assume independent censoring conditional on baseline covariates. In contrast, our setting considers time-varying treatments and allows censoring to depend on the evolving patient history, requiring only sequential independent censoring. This makes the previous methods unsuitable for our task.

HSTE estimation under time-varying treatments. In recent years, several approaches have been proposed to estimate heterogeneous treatment effects under time-varying treatments (e.g., [29, 8, 10] (Li et al. 2021)). However, these methods do not account for censoring and thus are not suitable for HSTE estimation. A limited literature lies at the intersection of heterogeneous effect estimation, survival outcomes, and time-varying treatments. Zhu and Gallego [51] estimate conditional survival effects from longitudinal data using recurrent neural networks. However, they explicitly assume that future covariates are independent of previous treatments, thereby excluding treatment–confounder feedback. Jun et al. [19] study heterogeneous survival effects across sequential antibiotic decisions using causal survival forests. However, they focus on an application-specific problem rather than developing a general learner for HSTE estimation under time-varying treatments. Closest to our setting, Abraich [1] directly considers counterfactual survival under time-varying treatment sequences in the presence of treatment–confounder feedback, and targets conditional survival contrasts between alternative treatment sequences. Their approach relies on sequential representation balancing and a discriminative survival model. However, it lacks the favorable properties of double robustness and Neyman-orthogonality, and is therefore first-order sensitive to nuisance misspecification.

Research Gap. To the best of our knowledge, an HSTE learner that has the favorable properties of double robustness and Neyman-orthogonality while properly handling time-varying confounding and history-dependent censoring is missing.2

Problem Setting

Notation. Capital letters denote random variables and lowercase letters their realizations. We write P(⋅)\mathbb{P}(\cdot) for probabilities and E[⋅]\mathbb{E}[\cdot] for expectations. We use E[Z∣X=x]\mathbb{E}[Z \mid X = x] to denote a fitted conditional-mean regression of ZZ on XX, not an empirical average. Estimated quantities carry a hat, as in f^\hat{f}. Time is discrete and indexed by k∈N0k \in\mathbb{N}_0. For a process UU, we write Uˉk:=(U0,…,Uk)\bar{U}_k := (U_0,\ldots,U_k) for its trajectory up to kk and Uˉr:s:=(Ur,…,Us)\bar{U}_{r:s} := (U_r,\ldots,U_s) for a contiguous segment. Throughout, WW denotes static baseline covariates, XkX_k time-varying covariates, Ak∈AA_k \in\mathcal{A} the treatment assigned at decision time kk, and T,C∈{1,2,…}T,C \in\{1,2,\ldots\} the event and censoring times, respectively. We denote by Hˉk:=(W,Xˉk,Aˉk−1)\bar{H}_k := (W,\bar{X}_k,\bar{A}_{k-1}) the pre-treatment history, i.e. all information available immediately before assigning AkA_k, and by Ek:=1{T>k,C>k}E_k := \mathbb{1}\{T > k,C > k\} the at-risk indicator. Potential quantities under a finite treatment sequence aˉ\bar{a} followed by natural-course treatment are written with a superscript, as in T(aˉ,nat)T^{(\bar{a},\mathrm{nat})}.

Setup. We consider a discrete-time longitudinal setting with i.i.d. patient trajectories and no common maximum follow-up length. Within each interval, we assume a strict temporal ordering: at the beginning of interval kk the covariates XkX_k of patients at risk are recorded, treatment AkA_k is assigned, and the patient is then monitored for the event or for censoring during [k,k+1)[k,k+1). Active treatment AkA_k is thus observed only for patients with Ek=1E_k = 1. A patient censored exactly at time cc still contributes the terminal covariates XcX_c, and hence the successor history Hˉc\bar{H}_c, but neither receives AcA_c nor contributes any later variable; conversely, an event preempts the next covariate measurement. Writing T~:=min⁡{T,C}\widetilde{T} := \min\{T,C\} for the terminal follow-up time and Δ:=1{T≤C}\Delta:= \mathbb{1}\{T \le C\} for the event indicator, the observed data for patient ii are Oi=(Wi,{Xik}k=0T~i−Δi,{Aik}k=0T~i−1,T~i,Δi),i=1,…,nO_i = (W_i,\{X_{ik}\}_{k=0}^{\widetilde{T}_i-\Delta_i},\{A_{ik}\}_{k=0}^{\widetilde{T}_i-1},\widetilde{T}_i,\Delta_i), i = 1,\ldots,n.

Finite-duration interventions with natural-course continuation. Acute clinical protocols prescribe treatment only for a limited period. We therefore fix a landmark time tt, an active intervention length L≥1L \ge1, and a survival horizon τ≥L\tau\ge L, and restrict attention to patients with Et=1E_t = 1. Within the follow-up window, δ=0,…,τ−1\delta= 0,\ldots,\tau-1 denotes the relative time offset, corresponding to absolute time t+δt+\delta. The final prescribed decision occurs at t+L−1t+L-1, and the evaluation time is t+τt+\tau. A deterministic sequence aˉt:t+L−1:=(at,…,at+L−1)∈AL\bar{a}_{t:t+L-1} := (a_t,\ldots,a_{t+L-1}) \in\mathcal{A}^{L} is applied during the LL intervals [t,t+1),…,[t+L−1,t+L)[t,t+1),\ldots,[t+L-1,t+L). Afterwards no further treatment is imposed and care evolves according to the natural assignment mechanism observed in the data: πk(a∣hˉk):=P(Ak=a∣Hˉk=hˉk,Ek=1)\pi_k(a \mid\bar{h}_k) := \mathbb{P}(A_k = a \mid\bar{H}_k = \bar{h}_k, E_k = 1), k∈N0k \in\mathbb{N}_0. We write T(aˉt:t+L−1,nat)T^{(\bar{a}_{t:t+L-1},\mathrm{nat})} for the potential event time under this regime. Figure 1 shows our problem setting.

Heterogeneous survival target. We target survival at a prespecified survival horizon. This choice corresponds directly to clinical endpoints such as 10-day survival. Our objective is therefore a horizon-specific counterfactual survival effect. Suppressing the natural-course continuation from the superscript, our target is the conditional survival function

St,τaˉ(hˉt):=P(T(aˉt:t+L−1,nat)>t+τ∣Hˉt=hˉt,Et=1).(1)S^{\bar{a}}_{t,\tau}(\bar{h}_t) := \mathbb{P}\left(T^{(\bar{a}_{t:t+L-1},\mathrm{nat})} > t + \tau\mid\bar{H}_t = \bar{h}_t, E_t = 1\right). \tag*{(1)}

that is, the probability that a patient at risk at the landmark with history hˉt\bar{h}_t survives through t+τt+\tau when treated according to aˉt:t+L−1\bar{a}_{t:t+L-1} and then following the natural course. For τ=L\tau= L the evaluation time coincides with the end of the intervention window, whereas τ>L\tau> L additionally captures its downstream consequences. For two candidate sequences aˉt:t+L−1\bar{a}_{t:t+L-1} and bˉt:t+L−1\bar{b}_{t:t+L-1}, the heterogeneous survival treatment effect is

θt,τaˉ,bˉ(hˉt):=St,τaˉ(hˉt)−St,τbˉ(hˉt).(2)\theta^{\bar{a},\bar{b}}_{t,\tau}(\bar{h}_t) := S^{\bar{a}}_{t,\tau}(\bar{h}_t) - S^{\bar{b}}_{t,\tau}(\bar{h}_t). \tag*{(2)}

Throughout the methodological development, tt, LL, and τ\tau are fixed, and we therefore write SaˉS^{\bar{a}} and θaˉ,bˉ\theta^{\bar{a},\bar{b}} when no ambiguity arises.

Identification. For the treatment process, we assume the standard identification conditions for longitudinal interventions: (A1) Consistency, if the observed treatment path over the active intervention window agrees with aˉt:t+L−1\bar{a}_{t:t+L-1}, then the corresponding potential event time equals the observed event time; (A2) Sequential treatment exchangeability, At+δ⊥ ⁣ ⁣ ⁣⊥T(aˉt:t+L−1,nat)∣Hˉt+δ,Et+δ=1A_{t+\delta} \perp\!\!\!\perp T^{(\bar{a}_{t:t+L-1},\mathrm{nat})} \mid\bar{H}_{t+\delta}, E_{t+\delta} = 1, for δ=0,…,L−1\delta= 0,\ldots,L-1; and (A3) Treatment positivity, πt+δ(at+δ∣Hˉt+δ)>0\pi_{t+\delta}(a_{t+\delta} \mid\bar{H}_{t+\delta}) > 0 almost surely on histories compatible with the intervention, for δ=0,…,L−1\delta= 0,\ldots,L-1 [39, 40, 29, 13].

References

  1. [1]Abraich, A. (2025). Tv-survcaus: Dynamic representation balancing for causal survival analysis. arXiv preprint arXiv:2505.01785.arxiv.org/abs/2505.01785
  2. [2]Bai, X., Tsiatis, A. A., and O’Brien, S. M. (2013). Doubly-robust estimators of treatment-specific survival distributions in observational studies with stratified sampling. Biometries, 69(4):830–839.DOI
  3. [3]Bica, I., Alaa, A. M., Jordon, J., and van der Schaar, M. (2020). Estimating counterfactual treatment outcomes over time through adversarially balanced representations. In International Conference on Learning Representations.arxiv.org/abs/2002.04083
  4. [4]Boyer, C. B., Dahabreh, I. J., and Steingrimsson, J. A. (2025). Estimating and evaluating counterfactual prediction models. Statistics in Medicine, 44(23–24):e70287.DOI
  5. [5]Cui, Y., Kosorok, M. R., Sverdrup, E., Wager, S., and Zhu, R. (2023). Estimating heterogeneous treatment effects with right-censored data via causal survival forests. Journal of the Royal Statistical Society Series B: Statistical Methodology, 85(2):179–211.arxiv.org/abs/2001.09887
  6. [6]Curth, A., Lee, C., and van der Schaar, M. (2021). SurvTTE: Learning heterogeneous treatment effects from time-to-event data. In Advances in Neural Information Processing Systems, volume 34.arxiv.org/abs/2110.14001
  7. [7]Foster, D. J. and Syrgkanis, V. (2023). Orthogonal statistical learning. The Annals of Statistics, 51(3):879–908.arxiv.org/abs/1901.09036
  8. [8]Frauen, D., Hess, K., and Feuerriegel, S. (2025a). Model-agnostic meta-learners for estimating heterogeneous treatment effects over time. In The Thirteenth International Conference on Learning Representations.arxiv.org/abs/2407.05287
  9. [9]Frauen, D., Schröder, M., Hess, K., and Feuerriegel, S. (2025b). Orthogonal survival learners for estimating heterogeneous treatment effects from time-to-event data. In Advances in Neural Information Processing Systems (NeurIPS). arXiv:2505.13072.arxiv.org/abs/2505.13072
  10. [10]Garriga, T., Melnychuk, V., Hess, K., de Cambra, E. S., Brando, A., Sanz, G., and Feuerriegel, S. (2026a). Orthogen: A generative orthogonal learner for time-varying treatments. arXiv preprint arXiv:2610.10210.arxiv.org/abs/2610.10210
  11. [11]Garriga, T., Sanz, G., de Cambra, E. S., and Brando, A. (2026b). CEPPAE: Conditional entropy-penalized autoencoders for time series counterfactuals. Transactions on Machine Learning Research.
  12. [12]Hernán, M. A., Brumback, B., and Robins, J. M. (2000). Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology, 11(5):561–570.
  13. [13]Hernán, M. A. and Robins, J. M. (2020). Causal Inference: What If. Chapman & Hall/CRC, Boca Raton.
  14. [14]Hess, K., Frauen, D., Melnychuk, V., and Feuerriegel, S. (2026a). IGC-net for conditional average potential outcome estimation over time. In The Fourteenth International Conference on Learning Representations.
  15. [15]Hess, K., Frauen, D., van der Schaar, M., and Feuerriegel, S. (2026b). Overlap-weighted orthogonal meta-learner for treatment effect estimation over time. In The Fourteenth International Conference on Learning Representations.arxiv.org/abs/2510.19643
  16. [16]Huang, X., Ning, J., and Wahed, A. S. (2014). Optimization of individualized dynamic treatment regimes for recurrent diseases. Statistics in Medicine, 33(14):2363–2378.DOI
  17. [17]Hubbard, A. E., van der Laan, M. J., and Robins, J. M. (2000). Nonparametric locally efficient estimation of the treatment specific survival distribution with right censored data and covariates in observational studies. In Halloran, M. E. and Berry, D. A., editors, Statistical Models in Epidemiology, the Environment, and Clinical Trials, volume 116 of The IMA Volumes in Mathematics and its Applications, pages 135–177. Springer, New York.DOI
  18. [18]Johnson, A. E., Bulgarelli, L., Shen, L., Gayles, A., Shammout, A., Horng, S., Pollard, T. J., Hao, S., Moody, B., Gow, B., et al. (2023). MIMIC-IV, a freely accessible electronic health record dataset. Scientific Data, 10(1):1.DOI
  19. [19]Jun, I., Cohen, S. A., Ser, S. E., Marini, S., Lucero, R. J., Bian, J., and Prosperi, M. (2023). Optimizing dynamic antibiotic treatment strategies against invasive methicillin-resistant staphylococcus aureus infections using causal survival forests and g-formula on statewide electronic health record data. In The KDD’23 Workshop on Causal Discovery, Prediction and Decision, pages 98–115. PMLR.pubmed.ncbi.nlm.nih.gov/37854935
  20. [20]Kang, J. D. Y. and Schafer, J. L. (2007). Demystifying double robustness: A comparison of alternative strategies for estimating a population mean from incomplete data. Statistical Science, 22(4):523–539.
  21. [21]Kennedy, E. H. (2023). Towards optimal doubly robust estimation of heterogeneous causal effects. Electronic Journal of Statistics, 17(2):3008–3049.arxiv.org/abs/2004.14497
  22. [22]Keogh, R. H., Gran, J. M., Seaman, S. R., Davies, G., and Vansteelandt, S. (2023). Causal inference in survival analysis using longitudinal observational data: Sequential trials and marginal structural models. Statistics in Medicine, 42(13):2191–2225.
  23. [23]Keogh, R. H. and van Geloven, N. (2024). Prediction under interventions: evaluation of counterfactual performance using longitudinal observational data. Epidemiology, 35(3):329–339.
  24. [24]Klein, J. P. and Moeschberger, M. L. (2003). Survival analysis: techniques for censored and truncated data. Springer.
  25. [25]Lee, C., Yoon, J., and van der Schaar, M. (2020). Dynamic-DeepHit: A deep learning approach for dynamic survival analysis with competing risks based on longitudinal data. IEEE Transactions on Biomedical Engineering, 67(1):122–133.DOI
  26. [27]Lim, B., Alaa, A. M., and van der Schaar, M. (2018). Forecasting treatment responses over time using recurrent marginal structural networks. In Advances in Neural Information Processing Systems (NeurIPS), volume 31.
  27. [28]Louizos, C., Shalit, U., Mooij, J., Sontag, D., Zemel, R., and Welling, M. (2017). Causal effect inference with deep latent-variable models. In Guyon, I., Luxburg, U. V., Bengio, S., Wallach, H., Fergus, R., Vishwanathan, S., and Garnett, R., editors, Advances in Neural Information Processing Systems, volume 30. Curran Associates, Inc.arxiv.org/abs/1705.08821
  28. [29]Melnychuk, V., Frauen, D., and Feuerriegel, S. (2022). Causal transformer for estimating counterfactual outcomes. In International conference on machine learning, pages 15293–15329. PMLR.arxiv.org/abs/2204.07258
  29. [30]Meneghini, L., Koenen, C., Weng, W., and Selam, J.-L. (2007). The usage of a simplified self-titration dosing guideline (303 algorithm) for insulin determining in patients with type 2 diabetes: results of the randomized, controlled predictive 303 study. Diabetes, Obesity and Metabolism, 9(6):902–913.DOI
  30. [31]Mesinovic, M., Watkinson, P., and Zhu, T. (2024). DySurv: dynamic deep learning model for survival analysis with conditional variational inference. Journal of the American Medical Informatics Association, 33(1):112–122.DOI
  31. [32]Morzywolek, P., Decruyenaere, J., and Vansteelandt, S. (2023). On a general class of orthogonal learners for the estimation of heterogeneous treatment effects. arXiv preprint arXiv:2303.12687.
  32. [33]Nie, X. and Wager, S. (2021). Quasi-oracle estimation of heterogeneous treatment effects. Biometrika, 108(2):299–319.arxiv.org/abs/1712.04912
  33. [34]Parafita, A. and Vitria, J. (2022). Estimand-agnostic causal query estimation with deep causal graphs. IEEE Access, 10:71370–71386.DOI
  34. [35]Pawlowski, N., Coelho de Castro, D., and Glocker, B. (2020). Deep structural causal models for tractable counterfactual inference. In Larochelle, H., Ranzato, M., Hadsell, R., Balcan, M., and Lin, H., editors, Advances in Neural Information Processing Systems, volume 33, pages 857–869. Curran Associates, Inc.
  35. [36]Petersen, M., Schwab, J., Gruber, S., Blaser, N., Schomaker, M., and van der Laan, M. J. (2014). Targeted maximum likelihood estimation for dynamic and static longitudinal marginal structural working models. Journal of Causal Inference, 2(2):147–185.pubmed.ncbi.nlm.nih.gov/25909047
  36. [37]Press, O. W., Li, H., Schöder, H., Straus, D. J., Moskowitz, C. H., et al. (2016). Us intergroup trial of response-adapted therapy for stage iii to iv hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest oncology group s0816. Journal of Clinical Oncology, 34(17):2020–2027.DOI
  37. [38]Punt, C. J. A., Buyse, M., Köhne, C.-H., Hohenberger, P., Labianca, R., Schmoll, H. J., Pählman, L., Sobrero, A., and Douillard, J.-Y. (2007). Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials. JNCI: Journal of the National Cancer Institute, 99(13):998–1003.pubmed.ncbi.nlm.nih.gov/17596575
  38. [39]Robins, J. M. (1986). A new approach to causal inference in mortality studies with a sustained exposure period—application to control of the healthy worker survivor effect. Mathematical Modelling, 7(9-12):1393–1512.DOI
  39. [40]Robins, J. M., Hernan, M. A., and Brumback, B. (2000). Marginal structural models and causal inference in epidemiology. Epidemiology, 11(5):550–560.pubmed.ncbi.nlm.nih.gov/10955408
  40. [41]Sanchez, P. and Tsaftaris, S. A. (2022). Diffusion causal models for counterfactual estimation. In First Conference on Causal Learning and Reasoning.arxiv.org/abs/2202.10166
  41. [42]Taubman, S. L., Robins, J. M., Mittleman, M. A., and Hernán, M. A. (2009). Intervening on risk factors for coronary heart disease: an application of the parametric g-formula. International journal of epidemiology, 38(6):1599–1611.DOI
  42. [43]van Geloven, N., Swanson, S. A., Ramspek, C. L., Luijken, K., van Diepen, M., Morris, T. P., Groenwold, R. H. H., van Houwelingen, H. C., Putter, H., and le Cessie, S. (2020). Prediction meets causal inference: the role of treatment in clinical prediction models. European Journal of Epidemiology, 35(7):619–630.DOI
  43. [44]Walia, A., Tuia, J., and Prasad, V. (2023). Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed. Nature Reviews Clinical Oncology, 20:885–895.DOI
  44. [45]Westling, T., Luedtke, A., Gilbert, P. B., and Carone, M. (2024). Inference for treatment-specific survival curves using machine learning. Journal of the American Statistical Association, 119(546):1541–1553.DOI
  45. [46]Xiong, H., Wu, F., Deng, L., Su, M., and Lehman, L.-w. H. (2024). G-transformer: Counterfactual outcome prediction under dynamic and time-varying treatment regimes. In Deshpande, K., Fiterau, M., Joshi, S., Lipton, Z., Ranganath, R., and Urteaga, I., editors, Proceedings of the 9th Machine Learning for Healthcare Conference, volume 252 of Proceedings of Machine Learning Research. PMLR.arxiv.org/abs/2406.05504
  46. [49]Zhang, M. and Schaubel, D. E. (2012). Contrasting treatment-specific survival using double-robust estimators. Statistics in Medicine, 31(30):4255–4268.DOI
  47. [50]Zheng, W., Petersen, M., and van der Laan, M. J. (2016). Doubly robust and efficient estimation of marginal structural models for the hazard function. The International Journal of Biostatistics, 12(1):233–252.
  48. [51]Zhu, J. and Gallego, B. (2022). Causal inference for observational longitudinal studies using deep survival models. Journal of Biomedical Informatics, 131:104119.DOI

Paper details

vlnc:W_wu97v5h7
Version
v1 · latest
Published
Fresh — added to the Hub within the last 30 days
Added
License
CC BY 4.0
Usage

views · 0

downloads · 0

A view counts once per browser per day, a download each time the PDF is requested.

  • Computer Science

Not recorded for this paper

View statement
Looking for related papers…
Contents